CB-1 Targeters For Obesity Dropping Fast
This article was originally published in The Pink Sheet Daily
Executive Summary
Psychiatric risk makes Merck’s taranabant the latest casualty.
You may also be interested in...
Orexigen Starts Partnership Talks On Obesity Drug Contrave
Firm stresses Phase III efficacy results will pass muster with FDA.
Orexigen Starts Partnership Talks On Obesity Drug Contrave
Firm stresses Phase III efficacy results will pass muster with FDA.
Obesity-Focused Zafgen Raises Zaftig Series B
Three years after its launch, Zafgen emerges from stealth mode with a new CEO and another $14 million in funding.